Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary

T Kita, Kita T, Y Kikuchi, Kikuchi Y, K Kudoh, Kudoh K, M Takano, Takano M, Goto T, T Goto, J Hirata, Hirata J, Tode T, T Tode, I Nagata, Nagata I
Oncology reports · 2000 · doi:10.3892/or.7.2.327 · PMID:10671681
other OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This study evaluated cisplatin-based chemotherapy for ovarian clear cell carcinoma, finding response rates of 22% for first-line CAP/CP and 40% for second-line CPT-P.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

This retrospective exploratory study evaluated clinical characteristics and treatment response in 53 patients with ovarian clear cell carcinoma treated between 1988 and 1997 at a single department, focusing on first- and second-line platinum-based chemotherapy regimens. All patients received postoperative platinum-based chemotherapy; first-line response to cisplatin-based combinations (CAP or CP) was assessed by CT scan or second-look laparotomy, with an overall response rate of about 22%. Second-line regimens showed higher response rates in this cohort, including 29% with EP/EJ (etoposide plus cisplatin/carboplatin) and 40% with CPT-P (CPT-11 plus cisplatin). The paper notes that while advanced-stage patients appeared to respond better to CPT-P, firm conclusions require studies with larger sample sizes, and response comparisons were not from randomized trials. Relevance to endometriosis: the study reports endometriosis in 55% of patients and states it was not a prognostic factor, thereby directly linking ovarian clear cell carcinoma chemotherapy outcomes to endometriosis status, though the paper’s main focus is chemotherapy response exploration.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Although clear cell carcinoma of the ovary is considered to be a tumor with poor prognosis, the clinical characteristics has not been defined. The aim of this study was to evaluate the response of clear cell carcinoma of the ovary to first and second-line chemotherapy and explore effective chemotherapy. Fifty-three patients with clear cell carcinoma of the ovary were enrolled between 1988 and 1997 at our department. Since taxol was not available in Japan at that time, cisplatin-based combination chemotherapy has been exclusively used as a standard first-line chemotherapy. Retrospective analyses of clinical characteristics and the response to first or second-line chemotherapy were performed. Median age was 52 years (range 27-71 years). Tumors were 34% (18/53) stage I, 19% (5/53) stage II, 38% (20/53) stage III, and 9% (5/53) stage IV. All patients with I or II stage disease had optimal cytoreduction. Out of 25 patients with III or IV stage disease 20% (5/25) had negative residual tumor, 36% (9/25) had /=2 cm residual tumor. All patients received postoperative platinum-based chemotherapy. Of 23 patients with measurable residual tumor 8.7% (2/23) completely and 13% (3/23) partially responded to first-line chemotherapy consisting of cisplatin, adriamycin and cyclophosphamide (CAP) or cisplatin and cyclophosphamide (CP) by CT scan or second look laparotomy. Presence of endometriosis was 55% (29/53) but was not a prognostic factor. Although overall response rate of ovarian clear cell carcinoma to first-line chemotherapy by CAP or CP was about 22%, EP or EJ consisting of etoposide and cisplatin or carboplatin used as a second-line chemotherapy showed 29% response rate, while CPT-P consisting of CPT-11 and cisplatin showed 40% response rate. Clear cell carcinomas were frequently present at early stage, with association of endometriosis and with poor overall prognosis. Although patients with advanced ovarian clear cell carcinoma seemed to have better response to CPT-P than conventional platinum-based chemotherapy, further studies are required with larger number of patients to draw firm conclusions.
Full text 4,715 characters · extracted from oa-doi-fallback · click to expand
Print ISSN: 1021-335X Online ISSN: 1791-2431 International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease. International Journal of Oncology is an international journal devoted to oncology research and cancer treatment. Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery. Oncology Reports is an international journal devoted to fundamental and applied research in Oncology. Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine. Oncology Letters is an international journal devoted to Experimental and Clinical Oncology. Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology. International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis. Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology. Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition. Publishes open-access research on using epigenetics to advance understanding and treatment of human disease. An International Open Access Journal Devoted to General Medicine. Article - Authors: - Pages: 327-358|Published online on: March 1, 2000https://doi.org/10.3892/or.7.2.327 - Expand metrics + Although clear cell carcinoma of the ovary is considered to be a tumor with poor prognosis, the clinical characteristics has not been defined. The aim of this study was to evaluate the response of clear cell carcinoma of the ovary to first and second-line chemotherapy and explore effective chemotherapy. Fifty-three patients with clear cell carcinoma of the ovary were enrolled between 1988 and 1997 at our department. Since taxol was not available in Japan at that time, cisplatin-based combination chemotherapy has been exclusively used as a standard first-line chemotherapy. Retrospective analyses of clinical characteristics and the response to first or second-line chemotherapy were performed. Median age was 52 years (range 27-71 years). Tumors were 34% (18/53) stage I, 19% (5/53) stage II, 38% (20/53) stage III, and 9% (5/53) stage IV. All patients with I or II stage disease had optimal cytoreduction. Out of 25 patients with III or IV stage disease 20% (5/25) had negative residual tumor, 36% (9/25) had /=2 cm residual tumor. All patients received postoperative platinum-based chemotherapy. Of 23 patients with measurable residual tumor 8.7% (2/23) completely and 13% (3/23) partially responded to first-line chemotherapy consisting of cisplatin, adriamycin and cyclophosphamide (CAP) or cisplatin and cyclophosphamide (CP) by CT scan or second look laparotomy. Presence of endometriosis was 55% (29/53) but was not a prognostic factor. Although overall response rate of ovarian clear cell carcinoma to first-line chemotherapy by CAP or CP was about 22%, EP or EJ consisting of etoposide and cisplatin or carboplatin used as a second-line chemotherapy showed 29% response rate, while CPT-P consisting of CPT-11 and cisplatin showed 40% response rate. Clear cell carcinomas were frequently present at early stage, with association of endometriosis and with poor overall prognosis. Although patients with advanced ovarian clear cell carcinoma seemed to have better response to CPT-P than conventional platinum-based chemotherapy, further studies are required with larger number of patients to draw firm conclusions. Copy and paste a formatted citation Spandidos Publications style Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J, Tode T and Nagata I: Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.. Oncol Rep 7: 327-358, 2000. APA Kita, T., Kikuchi, Y., Kudoh, K., Takano, M., Goto, T., Hirata, J. ... Nagata, I. (2000). Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.. Oncology Reports, 7, 327-358. https://doi.org/10.3892/or.7.2.327 MLA Kita, T., Kikuchi, Y., Kudoh, K., Takano, M., Goto, T., Hirata, J., Tode, T., Nagata, I."Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.". Oncology Reports 7.2 (2000): 327-358. Chicago Kita, T., Kikuchi, Y., Kudoh, K., Takano, M., Goto, T., Hirata, J., Tode, T., Nagata, I."Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.". Oncology Reports 7, no. 2 (2000): 327-358. https://doi.org/10.3892/or.7.2.327

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma, Clear Cell Antineoplastic Combined Chemotherapy Protocols Ovarian Neoplasms Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adult Aged Antineoplastic Combined Chemotherapy Protocols Cisplatin Cisplatin Cyclophosphamide Cyclophosphamide Female Humans Middle Aged Ovarian Neoplasms Ovarian Neoplasms Platinum Platinum Retrospective Studies

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-07-29T06:27:48.050232+00:00
pubmed
last seen: 2026-05-13T22:13:41.710148+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine